Ivana Vranić

1.9k total citations · 2 hit papers
30 papers, 1.2k citations indexed

About

Ivana Vranić is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Ivana Vranić has authored 30 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Rheumatology, 12 papers in Immunology and 6 papers in Hematology. Recurrent topics in Ivana Vranić's work include Rheumatoid Arthritis Research and Therapies (12 papers), Biosimilars and Bioanalytical Methods (7 papers) and Inflammatory Bowel Disease (6 papers). Ivana Vranić is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (12 papers), Biosimilars and Bioanalytical Methods (7 papers) and Inflammatory Bowel Disease (6 papers). Ivana Vranić collaborates with scholars based in United Kingdom, United States and Canada. Ivana Vranić's co-authors include Julián Panés, William J. Sandborn, Chinyu Su, Wojciech Niezychowski, Subrata Ghosh, Joseph Wu, Deepak L. Bhatt, Carol A. Connell, Cunshan Wang and Sujatha Menon and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Journal of Allergy and Clinical Immunology.

In The Last Decade

Ivana Vranić

28 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

2012 643 citations William J. Sandborn, Subrata Ghosh et al. New England Journal of Medicine profile →
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

2022 123 citations Christina Charles‐Schoeman, Maya H Buch et al. Annals of the Rheumatic Diseases profile →

Peers

Countries citing papers authored by Ivana Vranić

Since Specialization

Citations

This map shows the geographic impact of Ivana Vranić's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ivana Vranić with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ivana Vranić more than expected).

Fields of papers citing papers by Ivana Vranić

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ivana Vranić. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ivana Vranić. The network helps show where Ivana Vranić may publish in the future.

Co-authorship network of co-authors of Ivana Vranić

This figure shows the co-authorship network connecting the top 25 collaborators of Ivana Vranić. A scholar is included among the top collaborators of Ivana Vranić based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ivana Vranić. Ivana Vranić is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tofacitinib in early active axial spondyloarthritis: protocol of a randomized double-blind, placebo-controlled, multicenter phase IV study, FASTLANE 2025 ·Therapeutic Advances in Musculoskeletal Disease ·Valeria Ríos Rodríguez, Lídia Sànchez-Riera, Hildrun Haibel, (unknown), Murat Torğutalp, Fabian Proft, Judith Rademacher, Elke Binder, (unknown), Ivana Vranić, (unknown), Rajiv Mundayat, (unknown), Denis Poddubnyy	0
2	716 PREGNANCY OUTCOMES AFTER MATERNAL OR PATERNAL EXPOSURE IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAM 2024 ·Gastroenterology ·Uma Mahadevan, María Chaparro, (unknown), (unknown), Xiang Guo, Joseph Wu, Ivana Vranić, (unknown), Marla C. Dubinsky	4
3	Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure 2024 ·United European Gastroenterology Journal ·Julián Panés, Geert D’Haens, Bruce E. Sands, Siew C. Ng, Nervin Lawendy, (unknown), (unknown), Joseph Wu, Ivana Vranić, Remo Panaccione, Séverine Vermeire	19
4	Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis 2024 ·Advances in Rheumatology ·Atul Deodhar, Servet Akar, Jeffrey R. Curtis, Bassel Elzorkany, Marina Magrey, Cunshan Wang, Joseph Wu, Solomon B. Makgoeng, Ivana Vranić, Sujatha Menon, Dona Fleishaker, (unknown), Lara Fallon, Arne Yndestad, Robert Landewé	1
5	Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data 2024 ·Rheumatology and Therapy ·Lars Erik Kristensen, Atul Deodhar, Ying Ying Leung, Ivana Vranić, (unknown), Lara Fallon, (unknown), (unknown), Dafna D. Gladman	3
6	P956 Pregnancy outcomes after maternal or paternal exposure in the tofacitinib ulcerative colitis clinical programme 2024 ·Journal of Crohn s and Colitis ·Uma Mahadevan, María Chaparro, (unknown), (unknown), Xiang Guo, Jennifer W. Wu, Ivana Vranić, (unknown), Marla C. Dubinsky	2
7	Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis 2023 ·Rheumatology and Therapy ·Gerd R Burmester, Laura C. Coates, Stanley Cohen, Yoshiya Tanaka, Ivana Vranić, (unknown), Irina Lazariciu, (unknown), Kenneth Kwok, Lara Fallon, (unknown)	6
8	S1194 Tofacitinib for the Treatment of Ulcerative Colitis: Up to 9.2 Years of Safety Data From the Global Clinical Program 2023 ·The American Journal of Gastroenterology ·Julián Panés, Geert D’Haens, Bruce E. Sands, Siew C. Ng, Nervin Lawendy, (unknown), Xiang Guo, Joseph Wu, Ivana Vranić, Remo Panaccione, Séverine Vermeire	1
9	POS0674 RISK FACTORS FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS AGED ≥50 YEARS WITH RHEUMATOID ARTHRITIS AND ≥1 ADDITIONAL CARDIOVASCULAR RISK FACTOR: A POST HOC ANALYSIS OF ORAL SURVEILLANCE 2022 ·Annals of the Rheumatic Diseases ·Christina Charles‐Schoeman, Maya H Buch, (unknown), Deepak L. Bhatt, Jon T. Giles, (unknown), Gary G. Koch, Ivana Vranić, Jennifer W. Wu, C. Wang, S. Menon, Jose L. Rivas, (unknown), Carol A. Connell, Zoltán Szekanecz	4
10	Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance breakdown → 2022 ·Annals of the Rheumatic Diseases ·Christina Charles‐Schoeman, Maya H Buch, Maxime Dougados, Deepak L. Bhatt, Jon T. Giles, Steven R. Ytterberg, Gary G. Koch, Ivana Vranić, Joseph Wu, Cunshan Wang, Kenneth Kwok, Sujatha Menon, Jose L. Rivas, (unknown), Carol A. Connell, Zoltán Szekanecz	123
11	Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis 2022 ·Rheumatology and Therapy ·Roy Fleischmann, (unknown), Wuyan Zhang, (unknown), Ivana Vranić, Carol Cronenberger, Eva Dokoupilová	4
12	Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial 2022 ·Annals of the Rheumatic Diseases ·Jeffrey R. Curtis, Kunihiro Yamaoka, Yi‐Hsing Chen, Deepak L. Bhatt, (unknown), Naonobu Sugiyama, Carol A. Connell, Cunshan Wang, Joseph Wu, Sujatha Menon, Ivana Vranić, Juan J. Gómez‐Reino	91
13	Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial 2021 ·Arthritis Research & Therapy ·Roy Fleischmann, (unknown), (unknown), Carol Cronenberger, Ivana Vranić, Wuyan Zhang, Rieke Alten	12
14	AB0289 EFFICACY, SAFETY AND IMMUNOGENICITY IN PATIENTS WITH RHEUMATOID ARTHRITIS COMPARING PF-06410293 (ADL-PF), AN ADALIMUMAB (ADL) BIOSIMILAR, AND REFERENCE ADL: RESULTS FROM WEEK 26–52 OF A DOUBLE-BLIND, RANDOMISED PHASE 3 STUDY INCLUDING PATIENTS WHO SWITCHED FROM ADL-PF TO REFERENCE ADL AT WEEK 26 2020 ·Annals of the Rheumatic Diseases ·Roy Fleischmann, (unknown), (unknown), Carol Cronenberger, Ivana Vranić, (unknown), Rieke Alten	2
15	Influence of the Main Filter on QRS-amplitude and Duration in Human Electrocardiogram 2019 ·Measurement Science Review ·Ivana Vranić, (unknown), (unknown), Goran M. Stojanović, Hani Al‐Salami	0
16	Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial 2019 ·Journal of Allergy and Clinical Immunology ·Robert Bissonnette, Ana B. Pavel, Aisleen Diaz, John L. Werth, Chuanbo Zang, Ivana Vranić, Vivek S. Purohit, Michael A. Zielinski, Bonnie Vlahos, Yeriel Estrada, Étienne Saint‐Cyr Proulx, William C. Ports, Emma Guttman‐Yassky	95
17	565 Improvement in skin inflammation and barrier function biomarkers with crisaborole treatment in atopic dermatitis (AD) 2019 ·Journal of Investigative Dermatology ·Emma Guttman‐Yassky, Ana B. Pavel, Aisleen Diaz, J.L. Werth, Chuanbo Zang, Ivana Vranić, Vivek S. Purohit, Michael A. Zielinski, Bonnie Vlahos, Yeriel Estrada, (unknown), W.C. Ports, Robert Bissonnette	1
18	Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis breakdown → 2012 ·New England Journal of Medicine ·William J. Sandborn, Subrata Ghosh, Julián Panés, Ivana Vranić, Chinyu Su, (unknown), Wojciech Niezychowski	643
19	Phase 2 Study of CP-690,550, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis 2011 ·Gastroenterology ·William J. Sandborn, Subrata Ghosh, Julián Panés, Ivana Vranić, Chinyu Su, (unknown), Wojciech Niezychowski	9
20	Adenosine cardioprotection study in clinical setting of paroxysmal supraventricular tachycardia 2006 ·Prostaglandins Leukotrienes and Essential Fatty Acids ·Ivana Vranić, (unknown), Jovan Peruničić, Tijana Simić, (unknown), Nataša Milić	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact